P/B
19,5
Kura Oncology
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
$943M
Market Cap • 10/9/2026
2007
(19 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
12,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,5
EPS
—
Market Cap
Market Cap
943M
EV
448,4M
EV/Revenue
5,8
EV/EBITDA
-1,4
EV/EBIT
-1,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,3%
Total Yield
-0,3%
Payout
0%
Retained Earnings
-1,3B
Profitability
Gross Margin
99,3%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
336%
Capex/Revenue
7,3%
Capex/D&A
439,3%
Capex/OCF
-5,1%
SBC/OCF
—
% PPE
2,5%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
22,6%
CAGR Net Income 5Y
21%
CAGR EPS 5Y
12,9%
CAGR OCF 5Y
4%
Leverage
N.D./EBITDA
1,6
Debt/Equity
0%
Current Ratio
4,7
Quick Ratio
4,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!